Kevin Noonan

McDonnell Boehnen Hulbert & Berghoff LLP

Kevin Noonan is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s biotechnology and pharmaceuticals practice group.

Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.

Cell-based therapies are moving medical treatments forward, but intellectual property uncertainties may delay progress.